HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
BIOBOARD - EUROPE
Bone Therapeutics and Erasme University Hospital start Phase IIa trial in osteoporosis
Bone Therapeutics, an international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, announced that its partner, the Rheumatology Department of Erasme University Hospital (Brussels, Belgium), has initiated a Phase IIa trial with its lead bone cell therapy product PREOB® for the treatment of severe osteoporosis patients who do not respond to pharmacological treatment. 

PREOB® is Bone Therapeutics’ first-in-class autologous osteoblastic (bone forming) cell therapy product.  Due to its unique mechanism of action, PREOB® could have a significant role to play in the treatment of severe osteoporosis, where the majority of current treatments do not provide bone forming/anabolic activity as their mechanism of action and where over 40% of patients under treatment are still losing bone mass and fracture PREOB® is currently in two pivotal Phase III trials for the treatment of osteonecrosis and non-union fractures. 

This Phase IIa study is a six month open-label trial enrolling 20 patients with severe osteoporosis who do not respond to anti-osteoporotic treatment. PREOB® will be administered via a single intravenous infusion, and the primary endpoints of the trial will be cell body distribution and bone markers. The trial is the first of its kind to be initiated globally and will be run at the Erasme University Hospital (Free University of Brussels (ULB), Belgium).

Bone Therapeutics has been granted from the Free University of Brussels an exclusive worldwide license for PREOB® currently in Phase III clinical trials. Bone Therapeutics was founded in 2006 based on the pioneering works carried out at Erasme University Hospital-ULB, Brussels, Belgium. The Company still maintains close collaborations with scientific experts from various universities such as Prof. Gangji who is now head of the Rheumatology Department of the ULB Erasme Hospital.

Osteoporosis is a disease causing bone fragility and weakness and affects over 200 million people worldwide. Due to aging populations and growing awareness of the disease, the global market for osteoporosis therapeutics is expected to reach $8.8 billion in 2015.

Enrico Bastianelli, Chief Executive Officer of Bone Therapeutics, commented: “We are delighted to be expanding the potential of our lead product PREOB® to osteoporosis, a large disease area with significant unmet need, under the existing agreement that we have with the Free University of Brussels.”

Valérie Gangji, Head of Rheumatology, Erasme University Hospital commented: “We are very excited to be investigating the potential of PREOB® in treatment-resistant osteoporosis, where PREOB®'s unique mechanism of action could have a real impact on patients.  A new treatment such as PREOB® that could reduce the risk of fracture and the formation of new bone could significantly improve the quality of life of these osteoporotic patients.”

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy